

SARS-CoV-2 vaccination can elicit a CD8 T-cell dominant hepatitis

Tobias Boettler, Benedikt Csernalabics, Henrike Salié, Hendrik Luxenburger, Lara Wischer, Elahe Salimi Alizei, Katharina Zoldan, Laurenz Krimmel, Peter Bronsert, Marius Schwabenland, Marco Prinz, Carolin Mogler, Christoph Neumann-Haefelin, Robert Thimme, Maike Hofmann, Bertram Bengsch

Table of contents

Fig. S1.....2

Fig. S1.




Fig. S1. Immunophenotyping of EBV-specific CD8+ T cells

A: Longitudinal analysis of calculated *ex vivo* EBV-specific CD8+ T cell frequencies. **B:** Longitudinal analysis of CD38, **C:** Granzyme B (GrzB), **D:** Tbet+CD38hi CD8+ T cells are shown with time-matched ALT (U/l) levels depicted in grey with connected dots, circulating non-naïve EBV-specific CD8+ T cells (blue circle) Colored background indicates the patient's therapy regime (orange: budesonide, red: prednisolone).